ZBHZimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company that designs, develops, and distributes orthopedic and dental implants, surgical instruments, and related products. Its Q3 2026 Earnings Release on November 4, 2026 will test the durability of its recent 7.2% YoY revenue growth and the strength of its capital return program, including the $1 billion share repurchase plan and dividend sustainability.
- Revenue reached $8.34B in the second quarter of 2026, with a 7.2% year-over-year increase.
- Free cash flow totaled $2.74B in the trailing twelve months, supporting a net margin of 9.8%.
- Debt-to-equity ratio stands at 0.08x, reflecting a conservative capital structure.
The Read
4% mixed reaction to its 2026 Investor Day and capital allocation update.
The schedule
- Wed4Nov
- Tue9Feb
- Fri30Apr
- Mon9Aug
Past
- Wed5Aug
Actual outcome: Bull · $97.78 at outcome
Zimmer Biomet beat earnings estimates with an EPS of $1.03 versus the estimate of $1.03, and reported strong net sales growth of 4.8% on a reported basis. The company also raised its 2026 outlook, signaling confidence in future performance, which drove the stock higher and surpassed the bull target.
Quarterly earnings report focusing on elective procedure volumes and orthopedic demand.
- Wed20May
Actual outcome: Mixed · $84.98 at outcome
Zimmer Biomet provided a strong capital allocation update, announcing an increase in its share repurchase expectations to up to $1 billion by year-end—a $250 million increase from prior assumptions—and maintaining its quarterly dividend. Although the stock was initially flat through the outcome date, these shareholder-friendly moves ultimately drove shares significantly higher, easily surpassing the $87 bull target in the following months.
- Fri20Feb
Actual outcome: Bull · $98.44 at outcome
Zimmer Biomet reported Q4 2025 EPS of $0.71, exactly matching consensus estimates. Despite the lack of a headline earnings beat, the stock surged well past the $88.50 bull target to close at $98.44. This strong rally was driven by the company's robust 2026 forward guidance and positive outlook on procedural volumes, which reassured investors of sustained growth.
